UMB posted a recorded session on its YouTube channel covering how GLP-1 medicines work, plus their benefits and risks.
Recap by typeshit. Post by @umbaltimore on Instagram.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
New research points to weight loss drugs as the leading factor behind rising insurance costs in the state.
The cardiothoracic surgeon covers the newly published New England Journal of Medicine results from Lilly's phase 3 retatrutide trial.
Loading…